贝伐单抗联合化疗一线治疗晚期非鳞非小细胞癌临床观察

摘要

Objective To observe the effect of bevacizumab combined with platinum two drug regimen in ifrst-line for advanced (non-small cell lung cancer, NSCLC) evaluate the safety of bevacizumab in clinical application. Methods 28 cases of patients with non-squamous type NSCLC were treated with bevacizumab in combination with platinum for two treatment, efifcacy was evaluated every 2 cycles, the improvement in quality of life and treated with drug toxicity were observed. Results The 28 patients completed 6 cycles of treatment, efifcacy in complete remission in 0 cases (0%), partial remission 9 cases (32.1%), stable in 11 cases (39.3%), disease progression 8 cases (28.6%);the objective response rate and 32.1%(9/28);disease control rate and 71.4%(20/28). The side effects can be tolerated in all patients, and more for groups andⅡtoxicity. Conclusion Bevacizumab combined with standard chemotherapy can obtain good effect for advanced non-small cell lung cancer(NSCLC), and improve the life quality of the patients, higher safety.%目的观察贝伐单抗联合含铂两药方案一线治疗晚期非鳞非小细胞肺癌（NSCLC）的近期疗效和生活质量，评价贝伐单抗临床应用的安全性。方法对28例非鳞型NSCLC患者采用贝伐珠单抗联合含铂两药方案治疗，每2周期评价近期疗效，观察患者的生活质量改善及药物毒性。结果28例患者均完成6个周期的治疗，近期疗效为完全缓解（CR）0例（0.0％），部分缓解（PR），9例（32．1％），稳定,（SD）11例（39．3％），疾病进展,（PD）8例（28.6％）；客观有效率（ORR）32．1％（9/28）；疾病控制率（DCR）71．4％（20/28）。患者对毒副作用均可耐受，且多为Ⅰ级和Ⅱ级毒性。结论贝伐珠单抗联合标准化疗方案可获得较好的疗效，且患者生活质量改善，其安全性较高。